A new publication referencing mazdutide appeared on September 29, 2026. The paper, titled "Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis," was published in Diabetes, Obesity and Metabolism.
The publication is described as a systematic review and meta-analysis examining the dual GLP-1/glucagon receptor agonist drug class in the context of overweight and obesity. Mazdutide is noted as part of this class in the publication record.
No specific findings, efficacy outcomes, or safety results from this publication were provided in the available event data. This brief reports only that the publication exists, its title, its journal, and its date of record. Readers seeking the underlying data should consult the publication directly through the listed source.
Mazdutide remains classified as an unapproved compound used in research settings. It has not received regulatory approval for any indication referenced in this publication. No conclusions about the compound's benefits or risks can be drawn from the publication title alone.
For additional background on mazdutide, including its classification and research status, see the compound overview linked with this brief.